Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set
- PMID: 23555613
- PMCID: PMC3605419
- DOI: 10.1371/journal.pone.0059014
Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set
Abstract
Background: Several attempts have been made to determine HIV-1 resistance from genotype resistance testing. We compare scoring methods for building weighted genotyping scores and commonly used systems to determine whether the virus of a HIV-infected patient is resistant.
Methods and principal findings: Three statistical methods (linear discriminant analysis, support vector machine and logistic regression) are used to determine the weight of mutations involved in HIV resistance. We compared these weighted scores with known interpretation systems (ANRS, REGA and Stanford HIV-db) to classify patients as resistant or not. Our methodology is illustrated on the Forum for Collaborative HIV Research didanosine database (N = 1453). The database was divided into four samples according to the country of enrolment (France, USA/Canada, Italy and Spain/UK/Switzerland). The total sample and the four country-based samples allow external validation (one sample is used to estimate a score and the other samples are used to validate it). We used the observed precision to compare the performance of newly derived scores with other interpretation systems. Our results show that newly derived scores performed better than or similar to existing interpretation systems, even with external validation sets. No difference was found between the three methods investigated. Our analysis identified four new mutations associated with didanosine resistance: D123S, Q207K, H208Y and K223Q.
Conclusions: We explored the potential of three statistical methods to construct weighted scores for didanosine resistance. Our proposed scores performed at least as well as already existing interpretation systems and previously unrecognized didanosine-resistance associated mutations were identified. This approach could be used for building scores of genotypic resistance to other antiretroviral drugs.
Conflict of interest statement
Figures
Similar articles
-
Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.AIDS. 2010 Jan 28;24(3):365-71. doi: 10.1097/QAD.0b013e32833338ba. AIDS. 2010. PMID: 19864933
-
Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine.J Antimicrob Chemother. 2010 Apr;65(4):752-60. doi: 10.1093/jac/dkq034. Epub 2010 Feb 17. J Antimicrob Chemother. 2010. PMID: 20164199
-
Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.J Infect Dis. 2008 Aug 15;198(4):470-80. doi: 10.1086/590156. J Infect Dis. 2008. PMID: 18598191
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy.AIDS Rev. 2002 Jul-Sep;4(3):148-56. AIDS Rev. 2002. PMID: 12416449 Review.
Cited by
-
Short Communication: HIV-DRLink: A Tool for Reporting Linked HIV-1 Drug Resistance Mutations in Large Single-Genome Data Sets Using the Stanford HIV Database.AIDS Res Hum Retroviruses. 2020 Nov;36(11):942-947. doi: 10.1089/AID.2020.0109. Epub 2020 Aug 27. AIDS Res Hum Retroviruses. 2020. PMID: 32683881 Free PMC article.
-
A farewell to didanosine: harm reduction and cost savings by eliminating use of didanosine.Int J STD AIDS. 2015 Oct;26(12):903-6. doi: 10.1177/0956462414554433. Epub 2014 Oct 2. Int J STD AIDS. 2015. PMID: 25281538 Free PMC article.
References
-
- Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352: 1725–1730. - PubMed
-
- Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853–860. - PubMed
-
- Vella S (1995) HIV pathogenesis and treatment strategies. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 10: S20–S23. - PubMed
-
- Grant RM, Feinberg MB (1996) HIV replication and pathogenesis. Current Opinion in Infectious Diseases 9: 7–13.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous